These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 22454535)

  • 21. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
    Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
    Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
    Oberoi RK; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
    Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
    Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
    Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Hoque MT; Kis O; De Rosa MF; Bendayan R
    Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
    Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
    Marchetti S; Pluim D; van Eijndhoven M; van Tellingen O; Mazzanti R; Beijnen JH; Schellens JH
    Invest New Drugs; 2013 Oct; 31(5):1125-35. PubMed ID: 23315030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S; Elmquist WF
    Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.
    Giri N; Shaik N; Pan G; Terasaki T; Mukai C; Kitagaki S; Miyakoshi N; Elmquist WF
    Drug Metab Dispos; 2008 Aug; 36(8):1476-84. PubMed ID: 18443033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
    Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
    AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.